Wegovy week 5 weight loss results: what actually happens at this stage

You're probably reading this at 10pm wondering if your pen is even working

That's a fair thought to have at week five. You've done five injections, you've navigated the nausea (or maybe it hasn't been as bad as you feared), and the number on the scale has shifted, but perhaps not dramatically. Here's the thing: Wegovy is built around a deliberate, graduated titration. The first four weeks are spent at 0.25mg, a dose whose primary job is settling your system rather than producing weight loss. By week five most people are a day or two into 0.5mg, the first true step up. The appetite effects of semaglutide take time to accumulate, and the body's response to a new dose tends to be most pronounced in the week or two after each increase. So if week five feels underwhelming, you are not an outlier, you are exactly where the schedule expects you to be. The full timeline of how Wegovy works covers this progression in more detail, but the short version is: steady early, meaningful by mid-treatment.

What people often notice around week five is less about the scale and more about appetite. Portions feel slightly smaller. The urge to snack after dinner softens. That shift, quiet as it is, matters, it's the mechanism doing its work. If you're curious about how this compares to the very beginning of treatment, what week 1 on Wegovy actually looks like for weight loss gives you a useful reference point for how far you've already come.

What the trial data shows about early-phase weight loss on semaglutide

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks. The 15% average body weight reduction in that trial accumulated gradually, with the steepest losses coming after the maintenance dose of 2.4mg was reached and sustained. Trial data broken down by early time points consistently shows that weeks one through eight account for a relatively small proportion of total loss, most participants had lost somewhere between 2% and 4% of body weight by week eight, with wide individual variation. Week five sits right inside that variable window. Some people report two or three kilograms down; others report less than one. Both are plausible on the same dose. For those who want to understand what typical early numbers look like, the results people actually see in their first week on Wegovy helps set realistic expectations for the whole early phase.

For a broader look at how results accumulate over time, the week-by-week breakdown of Wegovy outcomes sets the early weeks in context against the full 68-week curve. The key takeaway from the clinical evidence is that early loss does not reliably predict final loss, people who start slowly often catch up substantially once they reach their therapeutic dose.

Side effects at week five: what's normal and when to get help

Week five is often when side effects shift slightly, either they've largely settled from the first weeks, or the move to 0.5mg reintroduces a mild wave of nausea or digestive change. The most commonly reported effects across the semaglutide programme are nausea, loose stools or constipation, indigestion and fatigue. These are covered in detail on the NHS semaglutide medicines page, which also lists the signs that warrant prompt medical attention.

Two things should prompt you to contact a doctor or call 111 rather than waiting it out: severe stomach pain that extends to your back (which can signal acute pancreatitis, a known but infrequent risk the MHRA has specifically highlighted for GLP-1 medicines), and signs of significant dehydration from persistent vomiting or diarrhoea. Neither is common, but both are serious. For milder nausea, eating smaller portions, avoiding high-fat meals, and staying upright after injecting are the practical steps most prescribers suggest. If you're a nume patient and something feels off, the aftercare team is available seven days a week, details on the contact page.

It's also worth knowing that you can report any suspected side effect directly to the MHRA via the Yellow Card scheme, patients can submit these themselves, not just clinicians.

Keeping week five in proportion (and what comes next

The dose schedule runs 0.25mg, 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg) each held for roughly four weeks before the next step, with 7.2mg now approved for some patients as a higher maintenance option. Week five is, on that map, still close to the start line. The months ahead involve dose increases that typically bring progressively greater appetite suppression and more noticeable weight changes. Many people find the 1.0mg and 1.7mg steps mark the point where they really notice Wegovy doing its work.

The practical things that matter at week five: keep your pen refrigerated between uses, rotate injection sites between abdomen, thigh and upper arm, and (if you order by noon on a weekday) your next pen arrives via DPD the following working day, so running out isn't something to leave to the last minute. For a fuller picture of the overall treatment journey, the Wegovy treatment overview covers eligibility, what the full schedule looks like, and how private access works alongside NHS routes. If you're comparing how week five feels against the whole arc of results, Wegovy's overall weight loss outcomes puts the clinical evidence together in one place. And if you're still deciding whether to start, checking your eligibility with our prescribers costs nothing and takes a few minutes.